Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Aquestive Therapeutics reported a Q2 2026 revenue increase driven by manufacturing and royalties and reaffirmed plans to resubmit its Anaphylm (dibutepinephrine) NDA to the FDA in Q3 2026 following successful human factors and pharmacokinetic studies. The company continues to advance its epinephrine AdrenaVerse platform, including AQST-108 for derm…